Myriad Genetics Inc

Myriad Genetics operates with a market capitalization of $369.27 million and a price-to-book ratio of 1.0, indicating that the market values the company at par with its book value. The company holds $149.60 million in cash and equivalents, while its long-term debt stands at $119.90 million, resulting in a debt-to-equity ratio of 0.33. The current ratio of 2.49 suggests a strong short-term liquidity position, with current assets significantly outpacing current liabilities. Profitability metrics reveal a challenging financial landscape for Myriad Genetics. The company reported a net loss of $365.90 million and an operating loss of $387.20 million, translating to a negative return on equity of -99.43% and a return on assets of -51.78%. These figures fall well below the industry median for profitability metrics, indicating a significant underperformance relative to its peers. The company's revenue is concentrated in a few key segments, with the majority derived from diagnostic services. Geographically, the U.S. accounts for the bulk of its revenue, with limited exposure to international markets. This concentration increases vulnerability to domestic regulatory and reimbursement changes. Looking ahead, Myriad Genetics is projected to see a modest improvement in revenue, with a year-over-year growth rate of approximately 2.5%. However, the company's free cash flow remains negative at -$339.10 million, driven by high operating losses and capital expenditures of -$27.40 million. The outlook for the next fiscal year is cautious, with analysts providing a mean price target of $7.03 and a median of $6.00. Risk factors for Myriad Genetics include its high net loss and operating loss, which could pressure liquidity if cash reserves are not replenished. The company has no immediate filing-based liquidity or dilution flags, and its dilution potential is assessed as low. However, the negative free cash flow and reliance on cash reserves could become a concern if operating performance does not improve. Recent events include the release of Q4 financial results, which highlighted the continued financial strain from the company's R&D and operational costs. No major regulatory or legal events were reported in the latest filings, but ongoing reimbursement pressures and competitive dynamics in the genetic testing market remain key concerns.